These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 36733927)
1. Co-delivery of gemcitabine and paclitaxel plus NanoCpG empowers chemoimmunotherapy of postoperative "cold" triple-negative breast cancer. Guo B; Qu Y; Sun Y; Zhao S; Yuan J; Zhang P; Zhong Z; Meng F Bioact Mater; 2023 Jul; 25():61-72. PubMed ID: 36733927 [TBL] [Abstract][Full Text] [Related]
2. Micellar paclitaxel boosts ICD and chemo-immunotherapy of metastatic triple negative breast cancer. Qiu X; Qu Y; Guo B; Zheng H; Meng F; Zhong Z J Control Release; 2022 Jan; 341():498-510. PubMed ID: 34883139 [TBL] [Abstract][Full Text] [Related]
3. A Dual-Targeting Liposome Enhances Triple-Negative Breast Cancer Chemoimmunotherapy through Inducing Immunogenic Cell Death and Inhibiting STAT3 Activation. Luo K; Yang L; Yan C; Zhao Y; Li Q; Liu X; Xie L; Sun Q; Li X Small; 2023 Oct; 19(40):e2302834. PubMed ID: 37264710 [TBL] [Abstract][Full Text] [Related]
4. Engineered exosomes as an in situ DC-primed vaccine to boost antitumor immunity in breast cancer. Huang L; Rong Y; Tang X; Yi K; Qi P; Hou J; Liu W; He Y; Gao X; Yuan C; Wang F Mol Cancer; 2022 Feb; 21(1):45. PubMed ID: 35148751 [TBL] [Abstract][Full Text] [Related]
5. Heat-Confined Tumor-Docking Reversible Thermogel Potentiates Systemic Antitumor Immune Response During Near-Infrared Photothermal Ablation in Triple-Negative Breast Cancer. Revuri V; Rajendrakumar SK; Park MS; Mohapatra A; Uthaman S; Mondal J; Bae WK; Park IK; Lee YK Adv Healthc Mater; 2021 Nov; 10(21):e2100907. PubMed ID: 34541833 [TBL] [Abstract][Full Text] [Related]
6. Turning foes to friends: Advanced " Wang Z; Sha T; Li J; Luo H; Liu A; Liang H; Qiang J; Li L; Whittaker AK; Yang B; Sun H; Shi C; Lin Q Bioact Mater; 2024 Sep; 39():612-629. PubMed ID: 38883315 [TBL] [Abstract][Full Text] [Related]
7. Paclitaxel/sunitinib-loaded micelles promote an antitumor response in vitro through synergistic immunogenic cell death for triple-negative breast cancer. Qin T; Xu X; Zhang Z; Li J; You X; Guo H; Sun H; Liu M; Dai Z; Zhu H Nanotechnology; 2020 Sep; 31(36):365101. PubMed ID: 32434167 [TBL] [Abstract][Full Text] [Related]
8. High-Dose Paclitaxel and its Combination with CSF1R Inhibitor in Polymeric Micelles for Chemoimmunotherapy of Triple Negative Breast Cancer. Lim C; Hwang D; Yazdimamaghani M; Atkins HM; Hyun H; Shin Y; Ramsey JD; Rädler PD; Mott KR; Perou CM; Sokolsky-Papkov M; Kabanov AV Nano Today; 2023 Aug; 51():. PubMed ID: 37484164 [TBL] [Abstract][Full Text] [Related]
9. A triple combination gemcitabine + romidepsin + cisplatin to effectively control triple-negative breast cancer tumor development, recurrence, and metastasis. Pattarawat P; Hunt JT; Poloway J; Archibald CJ; Wang HR Cancer Chemother Pharmacol; 2021 Sep; 88(3):415-425. PubMed ID: 34043046 [TBL] [Abstract][Full Text] [Related]
10. Codelivery of Shikonin and siTGF-β for enhanced triple negative breast cancer chemo-immunotherapy. Li J; Zhao M; Liang W; Wu S; Wang Z; Wang D J Control Release; 2022 Feb; 342():308-320. PubMed ID: 35031387 [TBL] [Abstract][Full Text] [Related]
11. Macrophage-camouflaged epigenetic nanoinducers enhance chemoimmunotherapy in triple negative breast cancer. Gao T; Sang X; Huang X; Gu P; Liu J; Liu Y; Zhang N Acta Pharm Sin B; 2023 Oct; 13(10):4305-4317. PubMed ID: 37799382 [TBL] [Abstract][Full Text] [Related]
12. Formulation of a triple combination gemcitabine plus romidepsin + cisplatin regimen to efficaciously and safely control triple-negative breast cancer tumor development. Pattarawat P; Wallace S; Pfisterer B; Odoi A; Wang HR Cancer Chemother Pharmacol; 2020 Jan; 85(1):141-152. PubMed ID: 31865420 [TBL] [Abstract][Full Text] [Related]
13. Enhanced Therapeutic Efficacy of Combining Losartan and Chemo-Immunotherapy for Triple Negative Breast Cancer. Zhao Q; He X; Qin X; Liu Y; Jiang H; Wang J; Wu S; Zhou R; Yu C; Liu S; Zhang H; Tian M Front Immunol; 2022; 13():938439. PubMed ID: 35812418 [TBL] [Abstract][Full Text] [Related]
14. Regulatory T cells: Their role in triple-negative breast cancer progression and metastasis. Malla RR; Vasudevaraju P; Vempati RK; Rakshmitha M; Merchant N; Nagaraju GP Cancer; 2022 Mar; 128(6):1171-1183. PubMed ID: 34990009 [TBL] [Abstract][Full Text] [Related]
15. Converging focal radiation and immunotherapy in a preclinical model of triple negative breast cancer: contribution of VISTA blockade. Pilones KA; Hensler M; Daviaud C; Kraynak J; Fucikova J; Galluzzi L; Demaria S; Formenti SC Oncoimmunology; 2020 Oct; 9(1):1830524. PubMed ID: 33150045 [TBL] [Abstract][Full Text] [Related]
16. Combination of thermally ablative focused ultrasound with gemcitabine controls breast cancer via adaptive immunity. Sheybani ND; Witter AR; Thim EA; Yagita H; Bullock TNJ; Price RJ J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32819975 [TBL] [Abstract][Full Text] [Related]
17. Camptothesome Potentiates PD-L1 Immune Checkpoint Blockade for Improved Metastatic Triple-Negative Breast Cancer Immunochemotherapy. Wang Z; Cordova LE; Chalasani P; Lu J Mol Pharm; 2022 Dec; 19(12):4665-4674. PubMed ID: 36413426 [TBL] [Abstract][Full Text] [Related]
18. Doxorubicin-polyglycerol-nanodiamond conjugate is a cytostatic agent that evades chemoresistance and reverses cancer-induced immunosuppression in triple-negative breast cancer. Yuan SJ; Xu YH; Wang C; An HC; Xu HZ; Li K; Komatsu N; Zhao L; Chen X J Nanobiotechnology; 2019 Oct; 17(1):110. PubMed ID: 31623629 [TBL] [Abstract][Full Text] [Related]
19. CXCL14 Attenuates Triple-Negative Breast Cancer Progression by Regulating Immune Profiles of the Tumor Microenvironment in a T Cell-Dependent Manner. Gibbs C; So JY; Ahad A; Michalowski AM; Son DS; Li Y Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012586 [TBL] [Abstract][Full Text] [Related]
20. Curcumin improves the therapeutic efficacy of Listeria(at)-Mage-b vaccine in correlation with improved T-cell responses in blood of a triple-negative breast cancer model 4T1. Singh M; Ramos I; Asafu-Adjei D; Quispe-Tintaya W; Chandra D; Jahangir A; Zang X; Aggarwal BB; Gravekamp C Cancer Med; 2013 Aug; 2(4):571-82. PubMed ID: 24156030 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]